Open AccessEarly Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients
Author(s) -
Κonstantinos Κostikas,
Alexander Mackay,
Claus Vogelmeier,
Stefan Frent,
Pritam Gupta,
Donald Banerji,
Francesco Patalano,
Pascal Pfister,
Jadwiga A. Wedzicha
Publication year - 2020
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s247966
Subject(s) - medicine , copd , indacaterol , exacerbation , salmeterol , minimal clinically important difference , odds ratio , randomized controlled trial , randomization , post hoc analysis , vital capacity , placebo , physical therapy , lung function , lung , diffusing capacity , alternative medicine , pathology
Chronic obstructive pulmonary disease (COPD) exacerbations are difficult outcomes to measure in clinical trials. It would be valuable to be able to predict which patients are likely to benefit in terms of exacerbation prevention based on their early response in lung function and symptoms.